News
-
DSP Clinical President And Founder Darlene Panzitta Named To The PharmaVOICE 100 List Of The Most Influential People In Life Sciences Industries
8/13/2012
Darlene Panzitta, President and Founder of DSP Clinical, is among this year's PharmaVOICE 100 List of the most influential people in lifes sciences industries.
-
Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis
8/8/2012
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).
-
Medical College Of Wisconsin To Study New Incontinence Device
8/7/2012
The Medical College of Wisconsin (MCW) has begun a clinical study of InTone®, a new, FDA-approved medical device that treats female urinary incontinence
-
Breast Cancer Patients Who Lack RB Gene Respond Better To Neoadjuvant Chemotherapy
7/26/2012
Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and theKimmel Cancer Center at Jefferson report in a retrospective study published in a recent online issue of Clinical Cancer Research.
-
EntreMed Announces Initiation Of Phase 2 Trial In Triple-Negative Breast Cancer
7/25/2012
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.
-
Cerulean Announces First Patient Dosed In Phase 2 Study Of CRLX101 In Ovarian Cancer
7/23/2012
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.
-
Ampio Advances NCE001 Cancer Drug Into Preclinical Development Following Successful Recent Financing And The Granting Of Patents In USA, Canada, Europe And China
7/16/2012
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs (Ampion™, Optina™, Zertane™ & Zertane-ED™) announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.
-
ActiGraph Introduces First Wireless Activity Monitor
7/12/2012
ActiGraph has announced the release of the wGT3X+ activity monitor, the first wireless device from the industry’s leading provider of objective 24 hour physical activity and sleep/wake monitoring hardware and software solutions.
- Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% Of Flu Deaths 7/10/2012
-
Oncos Therapeutics Announces Clinical Advisory Board For Its Oncolytic Virus And Cancer Immunotherapy Development Programs
7/5/2012
Oncos Therapeutics, the biotech company executing a clinical development program on its next generation oncolytic viruses, today announced the appointment of its Clinical Advisory Board (CAB).